Results 121 to 130 of about 108,162 (269)

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

Molecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce, Simone Bini, Marialuisa Sponziello, Giorgio Grani, Giulia Fiscon, Paola Paci, Lorenzo Farina, Rosa Falcone, Valentina Maggisano, Sebastiano Filetti, Cosimo Durante, Antonella Verrienti   +11 more
wiley   +1 more source

Use of cells and/or biologics combined with scaffolds in alveolar bone augmentation for implant site development. [PDF]

J Periodontol
Monje A, Soldini MC, Fahimipour F, Sarsri M, Geisinger ML.   +4 more
europepmc   +1 more source

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

Molecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge, Morten Tulstrup, Gabriele Todisco, Pedro Moura, Christophe Côme, Jakob Werner Hansen, Jakob Schmidt Jespersen, Balthasar Schlotmann, Maria Creignou, Mette Dahl, Claudia Schöllkopf, Klas Raaschou‐Jensen, Krister Wennerberg, Bo Porse, Joachim Weischenfeldt, Eva Hellström‐Lindberg, Lasse Sommer Kristensen, Kirsten Grønbæk   +17 more
wiley   +1 more source

719 Phase 1 clinical trial design of ZM008, a first-in-class anti LLT1 antibody is a promising therapy for multiple solid cancers

Journal for ImmunoTherapy of Cancer, 2023
Ignacio Garcia-Ribas, Maloy Ghosh, Anurag Tiwari, Sanghamitra Bhattacharjee, Yogendra Manjunath, Shalini Kashipathi, Subith Krishna, Ashvini Kumar Dubey, Tirtha Mandal, Soorya Gnanasegaran   +9 more
doaj   +1 more source

Early ileocaecal resection versus biologics therapy for localized Crohn disease: A systematic review and meta-analysis. [PDF]

Colorectal Dis
Bravin S, Menegat ALRS, Menegat BLRS, Kasimieh O, Wiederkehr H.   +4 more
europepmc   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

New technologies in oral reconstructive medicine: Consensus report of the AAP/OF/SEPA Workshop. [PDF]

J Periodontol
Sanz M, Ivanovski S, Nart J, Schwarz F, Wang HL, Aghaloo TL, Al-Nawas B, Avila-Ortiz G, Barootchi S, Blanco J, Blasi G, Donos N, Feher B, Dragan IF, Geisinger ML, Guerrero A, Ioannidou E, Kaigler D, Hernandez-Kapila Y, Kumar PS, Levin L, Liñares A, Mandelaris GA, Matesanz-Pérez P, Monje A, Montero E, Ortiz-Vigón A, Otomo-Corgel J, Pirih FQ, Ramanauskaite A, Rocchietta I, Ruiz-Magaz V, Saito H, Sánchez N, Sanz Esporrin J, Sculean A, Thieringer FM, Thoma DS, Valles C, Velásquez D, Wu DT, Giannobile WV.   +41 more
europepmc   +1 more source

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

Molecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera, Laura Vela‐Martín, Pablo Fernández‐Navarro, José Luis López‐Lorenzo, Javier Cornago, Pilar Llamas, Eduardo Pérez‐Gómez, José Luis Marín‐Rubio, Manuel Fresno, Javier Santos, José Fernández‐Piqueras, María Villa‐Morales   +11 more
wiley   +1 more source

Efficacy of Biologics in Patients with Moderate to Very Severe COPD: A Systematic Review. [PDF]

Int J Chron Obstruct Pulmon Dis
Brightling CE, Rabe KF, Singh D, Han MK, Bhutani M, Bourbeau J, Nair P, Drummond MB, Gandhi EA, Sindhwani NS, Molfino NA, Parulekar AD, Ponnarambil SS.   +12 more
europepmc   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source